NASHVILLE, Tenn., Oct. 1, 2024 /PRNewswire/ -- Pivot Point Consulting, a Vaco Holdings company and the #1 Best in KLAS:...
Progressive Care Stock to Cease Trading Today, October 1, 2024 COCONUT GROVE, Fla., Oct. 1, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ:...
Over 900 healthcare technology experts identified key data systems that fail to deliver ROI and siphon funds from providers after...
BERKELEY, Calif. and MAINZ, Germany, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),...
Ocean Biomedical’s Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of Cancers that include Lung...
CAMBRIDGE, MA and TAIPEI, TAIWAN / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Cenra Healthcare, the sales...
NEW YORK, Sept. 30, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The Global Health Intelligent Virtual...
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS) ("Biophytis" or the...
BALTIMORE, MD / ACCESSWIRE / September 30, 2024 / Tiffany Tate, CEO of VAULT Technologies and a recognized leader in...
Target enrollment in the chronic cohort close to completionVancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp....
CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the...
SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has...
Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives...
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or...
BUFFALO, NY / ACCESSWIRE / September 27, 2024 / POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical company, is pleased...
Announces completion of enrollment in its oral allergen challenge study for the development of its late-stage pipeline program, Anaphylm™ (epinephrine)...
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ETOCALA,...
GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a...
– Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor...
– Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 – – Retiring $17.5...